PMID- 20221326
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20240419
IS  - 1052-1372 (Print)
IS  - 1052-1372 (Linking)
VI  - 35
IP  - 2
DP  - 2010 Feb
TI  - Pharmacological and clinical differences between low-molecular-weight heparins: 
      implications for prescribing practice and therapeutic interchange.
PG  - 95-105
AB  - Thanks to their predictable pharmacokinetics and ease of use, 
      low-molecular-weight heparins (LMWHs) have established uses in the prevention and 
      treatment of thrombotic diseases and as a replacement for unfractionated heparin 
      (UFH). Although LMWHs as a class have similar antithrombotic effects, they 
      comprise a diverse group of agents with distinct biochemical and pharmacological 
      profiles. In light of the ongoing pressure to contain pharmacy costs, the 
      diversity among the LMWHs and their benefits over UFH are important 
      considerations in clinical practice.
FAU - Merli, Geno J
AU  - Merli GJ
FAU - Groce, James B
AU  - Groce JB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - P T
JT  - P & T : a peer-reviewed journal for formulary management
JID - 9015516
PMC - PMC2827912
OTO - NOTNLM
OT  - biosimilars
OT  - low-molecular-weight heparins
OT  - therapeutic equivalence
OT  - therapeutic interchange
EDAT- 2010/03/12 06:00
MHDA- 2010/03/12 06:01
PMCR- 2010/03/01
CRDT- 2010/03/12 06:00
PHST- 2009/10/27 00:00 [accepted]
PHST- 2010/03/12 06:00 [entrez]
PHST- 2010/03/12 06:00 [pubmed]
PHST- 2010/03/12 06:01 [medline]
PHST- 2010/03/01 00:00 [pmc-release]
AID - ptj35_2095 [pii]
PST - ppublish
SO  - P T. 2010 Feb;35(2):95-105.